Biogen Completes $5.3B Acquisition of Apellis to Expand Rare Disease Portfolio

Cambridge, MA, May 15, 2026 (Yahoo Finance) -- Biogen has completed its $5.3 billion acquisition of Apellis Pharmaceuticals. The deal strengthens Biogen’s presence in rare disease and complement-mediated disorder therapies. The company is expected to integrate Apellis’s portfolio into its broader neurology and specialty medicine strategy.

Read full article here.